Abstract
Correction to:Clinical and Translational Gastroenterology2020;11(3):e00140. https://doi.org/10.14309/ctg.0000000000000140 In the March 2020 issue of Clinical and Translational Gastroenterology, in “Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase” the authors would like to revise the Study Highlights section. The updated Study Highlights appears below.Study Highlights WHAT IS KNOWN ✓ Antiviral therapy is not recommended for patients with hepatitis B e antigen-positive chronic hepatitis B virus infection who have persistently elevated but normal alanine aminotransferase (pEDNA group). ✓ There is little consensus regarding early NUC treatment for pEDNA group. WHAT IS NEW HERE ✓ The cumulative hepatocellular carcinoma risk in the pEDNA group was minimal comparable with that of the inactive carrier group. TRANSLATIONAL IMPACT ✓ Among untreated pEDNA group, patients with an intermediate serum HBV DNA level are more likely to develop HCC. Further studies are needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
